September 14, 2018
ARLINGTON, Va. — Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the introduction of the Using Data to Prevent Opioid Diversion Act of 2018 (H.R. 6779) by Rep. Ken Buck (R-Colo.)
“HDA applauds the leadership of Rep. Buck in advancing new legislation that would enhance coordination and communication between pharmaceutical distributors and the Drug Enforcement Administration (DEA). The legislation takes an important step in providing much-needed clarity and definition around suspicious order monitoring and reporting, including the establishment of a centralized database. Further, the bill would broaden access to aggregated ARCOS data by manufacturers and distributors. Importantly, this bill will help foster greater information sharing between DEA and state regulators. These concepts build upon the forward-looking policy solutions HDA has advanced to respond to this crisis.
“As Congress considers a comprehensive response to the opioid epidemic, HDA and our distributor members look forward to working with legislators to continue advancing these common-sense and important reforms forward.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.